Cerebroprotective activity of 3-benzylxanthine derivative – compound Ale-15, in conditions of bilateral common carotid arteries ligation (ischemic stroke)

Sergey V. Levich¹*, Katherine V. Aleksandrova¹, Igor F. Belenichev², Alexander S. Shkoda¹

¹Department of Biochemistry and Laboratory Diagnostic, Zaporozhye State Medical University, Zaporozhye, 69035, Ukraine

Received: 4 October 2013
Revised: 7 October 2013
Accepted: 27 October 2013

*Correspondence to: Dr. Sergey V. Levich, Email: rshlevas@gmail.com

ABSTRACT

Background: Acute ischemic stroke is a leading cause of mortality, morbidity, long-term disability in industrialized countries. One of main parts of it pathogenesis is production of reactive oxygen species. The accumulation of them in neurons results in lipid peroxidation, protein oxidation, DNA damage, and finally cell death. Thereby the search of novel drugs, that have antioxidant action and can be used to complex treatment of cerebral strokes is reasonable. It is known, that xanthine derivatives exhibit a broad spectrum of biological activity, including antioxidant. So that, the goal of this research was to study in vivo neuroprotective action of water-soluble derivative of 3-benzylxanthine – morpholin-4-ium 3-benzylxanthinyl-8-methylthioacetate (Ale-15 compound) in comparison with neuroprotector-antioxidant – Mexidol.

Methods: Experimental part was done on white Wistar rats of both sexes of 220-260 g weight. For assessment of neuroprotective action of compound we used a model of global incomplete cerebral ischemia, that was reproduced by bilateral common carotid arteries ligation.

Results: It was studied an acute toxicity of Ale-15 compound, it influence on survival of laboratory animals, on progression of neurolgical deficit, on the content of adenylic nucleotides, on criteria of energy metabolism, on the activity of antioxidant enzymes and on oxidative modification of protein. Results of study showed, that injection of Ale-15 compound to animals with ischemic stroke intragastrically during 4 days positively reduced death rate and quantity of animals with serious neurologic symptoms. The main parts of Ale-15 cerebroprotective mechanism are antioxidant and anti-ischemic actions.

Conclusions: The performed study revealed significant cerebroprotective features of Ale-15 compound in conditions of experimental cerebrovascular accident.

Keywords: Xanthine, Antioxidant activity, Cerebroprotective action, Ischemic stroke

INTRODUCTION

In past years the prevalence growth of cardio-vascular diseases, that includes also cerebrovascular accidents (CVA), was noted.¹ Ischemic brain injuries are followed by serious neuralgic disorders, such as cognitive, motor, verbal impairment and other functions of central nervous system (CNS).² Acute ischemic stroke is a leading cause of mortality, morbidity, long-term disability in industrialized countries, and involves a complex array of processes involving multiple biological systems which collectively determine the susceptibility to and outcome from the ischemic event.³⁴

That is why the search for methods for pharmacological correction of these disorders and medications, that decrease degree of neurodegeneration in case of cerebral ischemia, is an essential issue of modern medicinal science.

Oxidative stress, defined as the accumulation of reactive oxygen species (ROS) plays a pivotal role in neurodegeneration associated with ischemia, trauma, and other neurodegenerative diseases.⁵ Er The accumulation of ROS in neurons results in lipid peroxidation, protein oxidation, DNA damage, and finally cell death.⁵⁹

Nowadays an active search for new cerebroprotectors is being carried out among compounds, that affect the compensatory shunt of ATP synthesis in conditions of...
cerebral ischemia, that modulate glutamate- and GABAergic systems, regulate activity of Ca-channels and system of nitrogen oxide, and also among antioxidants, neuropeptides, expression inhibitors of proinflammatory cytokines and antagonists of IL-1β-receptors.2,10

Strong interrelation between disorder of energetic and plastic metabolism, their effect on course and prognosis of disease are often ignored while making treatment regimens; the main pathogenic treatment is deemed to be hemodynamic recovery. Recently a lot of attention is concentrated on disorder of energy metabolism and on the abilities of its correction. A lot of scientists think, that metabolic support, that is realised not only in acute period of stroke, but also in post-acute, is a powerful preventive factor in respect to repeated strokes, disability and death of patients.11 Thereby the addition of drugs, that have energotropic, antioxidant, anti-ischemic and nootropic actions to complex treatment of cerebral strokes is reasonable.6,3,9,12

Substituted xanthine derivatives are an important class of pharmacologically active compounds that are known to exhibit various pharmacological properties including antioxidant.13,14 Earlier we mentioned about the synthesis of Ale-15 compound – (morpholin-4-i um 3-benzylxanthinyl-8-methylthioacetate) (Figure 1), that shows high antioxidant qualities in vitro.15

![Figure 1: Morpholin-4-i um 3-benzylxanthinyl-8-methylthioacetate – Ale-15.](image)

The goal of this research was to study in vivo neuroprotective action of Ale-15 compound in conditions of bilateral common carotid arteries ligation (ischemic stroke) and in comparison with pharmacological standard of neuroprotector-antioxidant – Mexidol.6,17

METHODS

Animals

Experimental part was done on white Wistar rats of both sexes of 220-260 g weight. All animals were on standard food ration of vivarium, with natural alteration of day and night. Rats were received from nursery of Institute of Pharmacology and Toxicology of Ukraine. All experimental procedures and operative interventions were done in accordance with WMA Statement on Animal Use in Biomedical Research.

Acute toxicity

Determination of acute toxicity of derivative xanthine was carried out by Kerber method in Loit modification, using Sidorov classification.18,19 For determination of median lethal dose (LD50) of Ale-15 compound under investigation it was injected intragastrically as water solution with the help of metal catheter one time to 5 groups (each route of entry) of laboratory animals, 6 animal units in each group. Several doses of Ale-15 were injected, including dose, which does not lead to death of any animal and dose, that leads to death of all the animals in group. After injection of Ale-15 the animals, that survived, were examined during two weeks.

Stroke model

For assessment of neuroprotective action of compound we used a model of global incomplete cerebral ischemia, that is the most adequate in terms of clinical implications of ischemic stroke20. This model was reproduced by bilateral common carotid arteries ligation that was performed under ethaminal-natrium anesthesia (40 mg/kg), with implication of surgical approach by means of separation of carotid arteries and single-step silk deligation.20 We took 1/20 LD50 as the relatively curative dose. The compound Ale-15 under research was injected once a day during the whole experiment at a dose of 50 mg/kg intragastrically with the help of metal catheter; Mexidol was injected according to the same schedule at a dose of 250 mg/kg intragastrically. The intact group was presented by pseudo-operated animals, that underwent the separation of carotid arteries under ethaminal-natrium anesthesia (40 mg/kg), with implication of surgical approach without deligation.

Biochemical analysis

Material: For assessment of severity of ischemic injury of cerebral tissues and pharmacocorrection efficiency we performed biochemical arterial blood analysis. For investigation of long-term results of pharmacocorrection we took brain from experimental animals the fourth day after the operation. We used cerebral cortex frontal lobes for biochemical investigation. For biochemical investigation cerebral tissues were homogenized in cold in salt isotonic solution (0.15 M KCl) at the temperature of +4°C with the help of glass homogenizer, in ratio tissue – salt solution 1:10. After that, we separated cytosolic fraction (15000 g) by means of differential centrifugation. Extract, deprived of proteins, was obtained precise weight of homogenate of cerebral tissue in 0.6 M solution of HClO4 with further neutralization with 5.0 M solution of potassium carbonate.21
State of antioxidant system: The state of antioxidant system was assessed by the activity of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), by index of oxidative modification of protein in cerebral tissue. Determination of SOD activity was carried out by method, that is specified by Chevary and coauthors.22 SOD activity was stated by c.u./mg of protein/min. Catalase activity was determined spectrophotometrically.23 Catalase activity was stated by unit/kg of protein/min. GPx activity was determined by method.24 The activity of GPx was stated by μmol/ GSH/mg of protein/min. The index of oxidative protein modification in cerebral tissues was determined with the help of method of B. Halliwell.25,26 For aldehyde phenylhydrazones (APH) the spector of absorption is indicated at 340 nm, and for carboxyl phenylhydrazones (CPH) the wave length was 363 nm.

The state of energy metabolism: The state of energy metabolism was determined by index of intermediates – ATP, ADP, AMP, lactate, pyruvate and malate. Ischemic injury of cerebral tissues was determined by hyperenzymemia of creatine phosphokinase (CPK). The creation of renovated form of NADH was determined by method of Hohorst.27 The activity of creatine phosphokinase-BB was determined after separation on the DEAE Sephadex A-50 with optical test according to Warburg.28 The activity of creatine phosphokinase-BB was stated by μkat/mg of protein/min. The quantity of malate was detected according to method of Zoh-Lompreht.29 The quantity of lactate used in reaction ia equal to the quantity of oxidized malate, malate, the growth of which is indicated at 340 nm. The quantity of pyruvate used in reaction ia equal to the quantity of oxidized lactate, the quantity growth of which is indicated at 340 nm.

Neurologic impairment: The neurologic impairment was determined by the scale stroke-index C.P. McGrow.29

Statistical analysis: The statistic data processing was carried out with the help of software for statistic data processing STATISTICA® for Windows 6.0 (StatSoft Inc. AXXR712D833214FAN5).30 The data is presented by sample mean ± standard error of the mean. The control of distribution normalcy was done in accordance with Shapiro-Wilk criteria. The fidelity of differences between experimental groups was estimated with the help of Student’s t-test and of Whitney-Mann test.

RESULTS

Acute toxicity

Intragastric injection of Ale-15 in a dose of 1050 mg/kg resulted in 100% mortality of the animals during the day, a dose of 850 mg/kg did not cause death. Injection of intermediate doses - 900, 950 and 1000 mg/kg caused death of 16.7%, 50% or 83.3% of animals respectively (table 1). The obtained experimental data showed that the test compound didn’t show significant toxicity, and its LD₅₀ was 950 ± 20 mg/kg.

Influence on survival and progression of neuralgic deficit

Double-sided common carotid arteries ligation caused serious neurologic changes in animals organisms, e.g. paralysis, paresis, ptosis, with maximum demonstration on the fourth day. So, the average score of uncured group of animals for this period corresponded to serious degree of neurologic symptoms according to C.P. McGrow scale (Table 2).

Table 1: Results of acute toxicity test in rats following intragastric injection of compound Ale-15 after 2 weeks of observation.

<table>
<thead>
<tr>
<th>Dose, mg/kg</th>
<th>850</th>
<th>900</th>
<th>950</th>
<th>1000</th>
<th>1050</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of survived rats on the 14th day, %</td>
<td>100</td>
<td>83.3</td>
<td>50</td>
<td>16.6</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2: Influence of Ale-15 on survival and progression of neuralgic deficit of animal in different periods on time after CVA on the 4th day.

<table>
<thead>
<tr>
<th>Animals group</th>
<th>Quantity of rats with serious symptoms, %</th>
<th>Average score acc. to C.P. McGrow scale</th>
<th>Proportion of operated/survived rats on the 4th day, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham surgery animals</td>
<td>0</td>
<td>2.00± 0.60</td>
<td>(5/5) 100</td>
</tr>
<tr>
<td>Animals with CVA</td>
<td>100</td>
<td>19.1± 7.64</td>
<td>(15/5) 33</td>
</tr>
<tr>
<td>Animals with CVA + Ale-15</td>
<td>76.9</td>
<td>10.8± 4.32*</td>
<td>(15/13) 86.7*</td>
</tr>
<tr>
<td>Animals with CVA + Mexidol</td>
<td>87.5</td>
<td>15.7± 3.2*</td>
<td>(15/8) 53*</td>
</tr>
</tbody>
</table>

Remark: * - p<0.05 in relation to control
On the 4th day in control group 33% of animals survived. Injection of Ale-15 compound to animals created evident cerebroprotective effect. So on the 4th day of experiment the average score of this group by C.P. McGraw scale was 10.8, and mortality decreased in comparison with control. However, 76.9% of animals showed serious neurologic deficit. Mexidol gave way to Ale-15 in terms of neuroprotective action.

**Influence on the content of adenylic nucleotides and on criteria of energy metabolism**

Biochemical investigations showed that double-sided common carotid arteries ligation led to typical ischemic disorders, such as deficit of macroergic phosphates, incoordination in the Krebs cycle, activity of anaerobic glycolysis and development of oxidative stress.

Injection of Ale-15 compound led to increasing of ATP level, malate level, pyruvate level, and decreasing in lactate content in comparison with control. In action of Mexidol we noted similar, but less evident effect in relation to criteria of bioenergetics (Tables 3 and 4).

**Table 3: Influence of Ale-15 on the content of adenylic nucleotides in brain and on the activity of creatine phosphokinase-BB in animals blood serum on the 4th day after CVA.**

<table>
<thead>
<tr>
<th>Animals group</th>
<th>ATP mcM/g of tissue</th>
<th>ADP mcM/g of tissue</th>
<th>AMP mcM/g of tissue</th>
<th>Creatine phosphokinase-BB mM/l/hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham surgery animals</td>
<td>2.01±0.12</td>
<td>0.53±0.005</td>
<td>0.12±0.003</td>
<td>0.04±0.003</td>
</tr>
<tr>
<td>Animals with CVA</td>
<td>1.07±0.07</td>
<td>0.24±0.003</td>
<td>0.27±0.002</td>
<td>0.17±0.005</td>
</tr>
<tr>
<td>Animals with CVA+Ale-15</td>
<td>1.71±0.11*</td>
<td>0.46±0.003*</td>
<td>0.12±0.008*</td>
<td>0.06±0.003*</td>
</tr>
<tr>
<td>Animals with CVA+Mexidol</td>
<td>1.33±0.12*</td>
<td>0.44±0.005*</td>
<td>0.15±0.011*</td>
<td>0.093±0.005*</td>
</tr>
</tbody>
</table>

Remark: * - p≤0.05 in relation to control

**Table 4: Influence of Ale-15 compound on criteria of energy metabolism in brain on the 4th day after CVA.**

<table>
<thead>
<tr>
<th>Animals group</th>
<th>Pyruvate mcM/g of tissue</th>
<th>Lactate mcM/g of tissue</th>
<th>Malate mcM/g of tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham surgery animals</td>
<td>0.51±0.06</td>
<td>2.7±0.02</td>
<td>0.26±0.03</td>
</tr>
<tr>
<td>Animals with CVA</td>
<td>0.22±0.02</td>
<td>9.2±0.07</td>
<td>0.11±0.01</td>
</tr>
<tr>
<td>Animals with CVA+Ale-15</td>
<td>0.50±0.02*</td>
<td>3.5±0.07*</td>
<td>0.44±0.03*</td>
</tr>
<tr>
<td>Animals with CVA+Mexidol</td>
<td>0.37±0.04*</td>
<td>4.9±0.03*</td>
<td>0.26±0.02*</td>
</tr>
</tbody>
</table>

Remark: * - p≤0.05 in relation to control

**Influence on the activity of antioxidant enzymes and oxidative modification of protein**

During the simulation of CVA we discovered increase of APH and KPH products of oxidative protein modification in cerebral tissues of rats on the 4th day (table 5). Injection of Mexidol led to decrease of neurotoxic products of oxidative modification of protein (OMP), that are APH and KPH. Ale-15 compound showed powerful antioxidant action in acute period of cerebral ischemia via oxidative protein modification suppression. It was illustrated by positively low level of APH and KPH in cerebral tissues of rats, that took course of Ale-15, in comparison with animals, that were not cured. In brains of animals, that underwent treatment with Ale-15, the increased activity of key antioxidant enzymes and the decrease of hyperenzymemia of creatine phosphokinase-BB was noted (Tables 3 and 6).

**Table 5: Influence of Ale-15 compound on oxidative modification of protein in brain on the 4th day after CVA.**

<table>
<thead>
<tr>
<th>Animals group</th>
<th>OPM products, c.u./g of protein</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APH (270 nm)</td>
</tr>
<tr>
<td></td>
<td>KPH (363 nm)</td>
</tr>
<tr>
<td>Sham surgery animals</td>
<td>6.2±0.42</td>
</tr>
<tr>
<td>Animals with CVA</td>
<td>19.7±3.77</td>
</tr>
<tr>
<td>Animals with CVA+Ale-15</td>
<td>8.1±0.37*</td>
</tr>
<tr>
<td>Animals with CVA+Mexidol</td>
<td>12.7±1.0*</td>
</tr>
</tbody>
</table>

Remark: * - p≤0.05 in relation to control

1. p≤0.05 in relation to animals group, that took Mexidol

---


**Table 6: Influence of Ale-15 on the activity of antioxidant enzymes in brain on the 4th day after CVA.**

<table>
<thead>
<tr>
<th>Animals group</th>
<th>SOD, c.u./mg of protein/min</th>
<th>Catalase, mol/Hb/mg of protein/ min</th>
<th>GPx, mcM/mg of protein/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham surgery animals</td>
<td>284.1±13.4</td>
<td>15.5±1.35</td>
<td>68.3±3.5</td>
</tr>
<tr>
<td>Animals with CVA</td>
<td>117.1±5.8</td>
<td>8.7±0.5</td>
<td>41.2±3.4</td>
</tr>
<tr>
<td>Animals with CVA+Ale-15</td>
<td>270.2±12.3*</td>
<td>14.0±0.70*</td>
<td>63.7±3.1*</td>
</tr>
<tr>
<td>Animals with CVA+Mexidol</td>
<td>187.3±9.7*</td>
<td>11.7±0.75*</td>
<td>47.5±7.7</td>
</tr>
</tbody>
</table>

Remark: * - p≤0.05 in relation to control

**DISCUSSION**

The performed investigation revealed significant cerebroprotective features of Ale-15 compound in conditions of experimental CVA. Injection of Ale-15 compound to animals with CVA in dose of 50 mg/kg/day intragastrically during 4 days reduced death rate and quantity of animals with serious neurologic symptoms (decrease by C.P. McGrow scale).

The main parts of Ale-15 cerebroprotective mechanism are anti-ischemic activity (intensification of aerobic reactions of ATP creation) and its antioxidant action (suppressing of nerve tissue oxidative protein modification), that was discovered and described for the first time in researches *in vitro*. Injection of Ale-15 compound led to increasing of ATP synthesis by means of activation of aerobic oxidation cycle, that is indicated by increasing of malate level, decreasing of lactate content, that is the evidence of decreasing lactate-acidosis in nerve tissue and increasing pyruvate level in comparison with control. It should be noted, that Ale-15 caused the increasing level of ATP on the background of decreasing level of AMP, that is pro-oxidant and thrombocyte aggregation inductor. Evidently the compound Ale-15 has positive impact on metabolism of adenylc nucleotides, intensifying AMP utilization, and thus leads to further retardation of xanthine oxidase reaction of ROS.

Injection of Ale-15 compound led to increasing of ATP synthesis by means of activation of aerobic oxidation cycle, that is indicated by increasing of malate level, decreasing of lactate content, that is the evidence of decreasing lactate-acidosis in nerve tissue and increasing pyruvate level in comparison with control. It should be noted, that Ale-15 caused the increasing level of ATP on the background of decreasing level of AMP, that is pro-oxidant and thrombocyte aggregation inductor. Evidently the compound Ale-15 has positive impact on metabolism of adenylc nucleotides, intensifying AMP utilization, and thus leads to further retardation of xanthine oxidase reaction of ROS.

The performed investigation revealed that by the strength of neuroprotective action Ale-15 compound exceeds pharmacological standard of neuroprotective and antioxidant action – Mexidol.

**Funding: No funding sources**
**Conflict of interest: None declared**
**Ethical approval: Approval taken**

**REFERENCES**


